Management intends to IPO once it completes Phase 1 and its proof-of-concept study to demonstrate efficacy. Data gathered measuring GRX-917’s ability to increase neurosteroids, along with efficacy data, should provide for a highly anticipated public offering.
Anxiety, which is frequently comorbid with depression, is the largest mental health issue in North America. It is estimated that one third of the North American adult population experiences anxiety issues, yet only one third of sufferers receive treatment, of whom only 10% experience any form of remission. This is [...]
On August 29, 2019 GABA Therapeutics Inc. secured up to $15.5 million of Series A investment from Atai Life Science AG, which will take the GRX-917 program through Phase 2a. ATAI Life Sciences AG is a global biotech platform and company builder, based in Berlin, London and New York, focused [...]
Early Beginnings The original, non-deuterated drug (etifoxine) was originally developed to compete with tranquilizing and sedative BZs of the 1960’s, such as Valium and Librium. But it was mischaracterized as a mild benzodiazepine, because of its lack of typical benzodiazepine side effects, like sedation and ataxia. Hoechst sold the rights [...]